Prelude Therapeutics (PRLD) Asset Utilization Ratio (2025 - 2026)

Prelude Therapeutics' (PRLD) quarterly Asset Utilization Ratio came in at 0.13 in Q1 2026, down 6.29% quarter-over-quarter from 0.14 in Q4 2025.

Prelude Therapeutics (PRLD) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

Prelude Therapeutics has disclosed Asset Utilization Ratio across 2 years of filings, most recently posting 0.13 for Q1 2026.

Asset Utilization Ratio for Q1 2026 came in at 0.13, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 0.13 (changed N/A YoY), and the FY2025 annual result was 0.08, up 148.06% from the prior year.
Asset Utilization Ratio came in at 0.13 for Q1 2026 at Prelude Therapeutics, down from 0.14 in the prior quarter.
In the past five years, Asset Utilization Ratio ranged from a high of 0.14 in Q4 2025 to a low of 0.13 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-	0.55
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn	0.60
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-	1,422.00
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn	0.47
9	Abivax	94.26 Bn	94.26 Bn	-	-
10	Prelude Therapeutics	314.40 Mn	169.80 Mn	-	0.13

Download Data